Related Experiment Video
Updated: May 25, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
What to Expect When Switching to a Biosimilar: A US Healthcare Professional's Perspective
Juanita Belton1, Nicholas D'Apice2
1Gastroenterology Department, Boston Medical Center, Boston, MA, USA.
Abstract:
As biosimilars become more available, many patients with inflammatory bowel disease may experience having their treatment switched from a reference product to a biosimilar. In this communication, a physician assistant and a pharmacist discuss the patient experience when switching to a biosimilar.
Related Concept Videos
Bioequivalence: Overview
Drug Nomenclature
Drug Biotransformation: Overview
Biopharmaceutics and Pharmacokinetics: Overview
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Introduction To Health Care Delivery System
The Institute of Medicine (IOM) advocates for a patient-centered, effective, safe, timely, equitable, and effective healthcare system. The National Priorities...

